783363-95-1Relevant academic research and scientific papers
Diamine compound, polyimide film and flexible display device
-
Paragraph 0108-0110; 0113, (2019/04/17)
The invention relates to the technical field of intelligent display, in particular to a diamine compound, a polyimide film and a flexible display device. The diamine compound has a structure shown ina formula (I) which is as shown in the specification, wherein the structure shown in the formula (I) meets one of the following conditions: i. at least one of A1-A4 is an N atom, the rest is -CH-, a structure shown in the specification is phenyl, five-membered heteroaryl or six-membered heteroaryl; ii. the A1-A4 are all -CH-, and the structure shown in the specification is five-membered aromatic heterocycles or six-membered aromatic heterocycles.
HCV NS5A replication complex inhibitors. Part 3
Lopez, Omar D.,Nguyen, Van N.,St. Laurent, Denis R.,Belema, Makonen,Serrano-Wu, Michael H.,Goodrich, Jason T.,Yang, Fukang,Qiu, Yuping,Ripka, Amy S.,Nower, Peter T.,Valera, Lourdes,Liu, Mengping,O'Boyle II, Donald R.,Sun, Jin-Hua,Fridell, Robert A.,Lemm, Julie A.,Gao, Min,Good, Andrew C.,Meanwell, Nicholas A.,Snyder, Lawrence B.
, p. 779 - 784 (2013/02/25)
In a recent disclosure,1 we described the discovery of dimeric, prolinamide-based NS5A replication complex inhibitors exhibiting excellent potency towards an HCV genotype 1b replicon. That disclosure dealt with the SAR exploration of the peripheral region of our lead chemotype, and herein is described the SAR uncovered from a complementary effort that focused on the central core region. From this effort, the contribution of the core region to the overall topology of the pharmacophore, primarily vector orientation and planarity, was determined, with a set of analogs exhibiting 50 in a genotype 1b replicon assay.
IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS
-
Page/Page column 47, (2010/02/09)
The preferred embodiments are directed to small molecule inhibitors of the IgE response to allergens, which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic. The preferred embodiments also relate to imidazole molecules that are cellular proliferation inhibitors and thus are useful as anticancer agents. The preferred embodiments further relate to small molecules which suppress cytokines and leukocytes.
